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University of Birmingham, Birmingham B15 2TT, United Kingdom; mCentre For Health Policy, University of Melbourne, Parkville, VIC 3010, Australia; and
nInstitute of Health Biomedical Innovation (IHBI), Queensland University of Technology, Brisbane, QLD 4059, Australia
Edited by Jens Heinmueller, Stanford University, Stanford, CA, and accepted by Editorial Board Member Mary C. Waters July 22, 2021 (received for review
December 23, 2020)
How does the public want a COVID-19 vaccine to be allocated?
We conducted a conjoint experiment asking 15,536 adults in
13 countries to evaluate 248,576 profiles of potential vaccine
recipients who varied randomly on five attributes. Our sample
includes diverse countries from all continents. The results sug-
gest that in addition to giving priority to health workers and to
those at high risk, the public favors giving priority to a broad
range of key workers and to those with lower income. These
preferences are similar across respondents of different education
levels, incomes, and political ideologies, as well as across most
surveyed countries. The public favored COVID-19 vaccines being
allocated solely via government programs but were highly polar-
ized in some developed countries on whether taking a vaccine
should be mandatory. There is a consensus among the public
on many aspects of COVID-19 vaccination, which needs to be
taken into account when developing and communicating rollout
strategies.
COVID-19 | vaccinations | public health | public opinion
How to allocate scarce COVID-19 vaccines is one of the mostimportant decisions governments around the world have
recently faced. COVID-19 vaccines have been developed at an
unprecedented speed. Several vaccines have been shown to be
safe and highly effective (1) and have received widespread reg-
ulatory approval (2). At the time of writing, there are also many
vaccine candidates undergoing human trials.
In many countries, because public confidence in vaccination
has been fragile, the policies for prioritizing vaccine allocation
have needed to be seen as both equitable and evidence based
(3). Ethical frameworks have been suggested for the allocation of
scarce vaccine supplies between countries (4). The World Health
Organization (WHO) has developed a values framework based
on 12 objectives and six principles (human well-being, equal
respect, global equity, national equity, reciprocity, legitimacy).
Importantly, the WHO does not provide any guidance on the
order of importance of either the principles or the objectives (5).
Constraints on timely supply of vaccines have meant that it is not
possible to secure all of the objectives simultaneously. The WHO
Strategic Advisory Group of Experts on Immunization proposed
a road map that prioritizes health workers and older adults (6).
The Oxford COVID-19 Vaccine Preference and Opinion Sur-
vey (CANDOUR) Project aims to measure the global public’s
preference for vaccine allocation priorities.
At a national level, governments rapidly developed guidelines
to prioritize access to COVID-19 vaccines. Based on a survey
of governments’ vaccine allocation policy plans, conducted in
early December 2020 (to coincide with the fieldwork for the
CANDOUR surveys), Table 1 indicates that there was, at that
time, considerable diversity across countries in the groups being
prioritized. While prioritization of health workers and the clini-
cally vulnerable was almost universal, there was little consensus
on which other groups to prioritize. The UK prioritization strat-
egy was largely age based, starting with the oldest age categories
followed by the clinically vulnerable (7), with no other criteria to
be employed until after everyone over 50 and/or with underly-
ing health conditions had been vaccinated. In contrast, an expert
committee in France had recommended prioritizing workers
who have contact with the general public, including shop work-
ers, school staff, transport staff, and hospitality workers. In the
United States, the Centers for Disease Control and Prevention
was deciding whether to prioritize essential workers (including
school staff, police, grocery workers, and bus drivers), adults over
65, and those of any age who have high-risk medical conditions
(8). Chile appeared to be planning yet a different strategy, priori-
tizing health care workers, other essential workers, and teachers.
In sum, there was substantial variation in who could get a vaccine
and when.∗
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*At the time of writing, countries appear to have broadly followed these initial plans.
When Chile formally announced its prioritization criteria in late December 2020, the
elderly and vulnerable were also included. Unsurprisingly, as vaccination programs have
progressed, a number of countries have expanded their priority lists. For example,
teachers became eligible in Canada, Colombia, Italy, Spain, Uganda, and the United
States. In India, younger people who were vulnerable due to comorbidities were pri-
oritized. Age became a priority in Spain, and essential infrastructure workers were
prioritized in both Spain and Italy. In Colombia, from early May, there has been a
greater emphasis on reducing transmission. It is also worth highlighting that the relative
focus on different priority groups has varied across countries. For instance, in China, the
focus seems to have been more on transmission, with 18- to 59-y-old cohorts vaccinated
before the elderly.
























How to allocate COVID-19 vaccines is one of the most impor-
tant decisions currently facing governments. With limited
supplies, what is most pressing is deciding who gets priority in
the vaccine allocation rollout. Some governments are explor-
ing allowing private purchases of COVID-19 vaccines. Many
countries are debating whether COVID-19 vaccines should be
mandated. There is little evidence on what policies are pre-
ferred by the global public. Our survey of 15,536 adults in
13 countries confirms that priority should be given to health
workers and those at high risk but also, to a broad range
of key workers and those with lower incomes. The public
favors allocating COVID-19 vaccines solely via government
programs but was polarized in some countries on mandatory
vaccinations.
Many health technology assessment (HTA) agencies involve
the public in decisions (9). Such processes have, however, been
largely absent from the development of guidelines for COVID-
19 vaccine prioritization. While HTA agencies often involve
patient representatives (10), wider input, including the use of cit-
izen juries (11) and surveys of public preferences [including use
of conjoint methods (12)], has long been advocated. While there
have been calls for the public to have a say in COVID-19 vac-
cine priority setting (13), to date empirical evidence on public
preferences has been very limited (11, 14, 15).
Beyond priority setting, governments have considered a num-
ber of vaccine policy measures that may, or may not, be seen by
the general public as equitable and fair. Some governments have
debated whether citizens should be able to purchase COVID-
19 vaccines from private providers. Indeed, COVID-19 vaccines
have been available for private purchase in India and Pakistan
since early March and April 2021, respectively, while the Aus-
tralian government has also indicated the potential for a private
market (16). On the other hand, in many countries there are no
plans for the private sale of COVID-19 vaccines (17).
Governments are also considering whether they should make
COVID-19 vaccination mandatory. At the time of writing, no
countries appear to have yet mandated COVID-19 vaccination
at a population level. However, Italy recently made vaccina-
tion mandatory for health care workers (18). There have also
been calls to make vaccination of children mandatory, provided
a COVID-19 vaccine that reduces transmission proves to be safe
in pediatric trials. There are strong ethical arguments (19) for
forms of coercion in public health to deal with the externalities
that arise from infectious diseases (i.e., those who refuse vac-
cination not only put themselves at risk but increase the risk
to others). While a recent international survey on factors that
could influence potential COVID-19 vaccine uptake indicated
that employer-mandated vaccination would decrease the like-
lihood of use, governments already have in place policies to
provide strong incentives for uptake of existing vaccines. The
merits of some form of mandating have already been subject to
considerable public discussion (20), and a recent ruling by the
European Court of Human Rights has potentially helped to clear
the legal pathway to doing so (21). Nonetheless, we do not know
whether, where, or to what extent mandates are supported by the
general public.
The successful rollout of COVID-19 vaccines will depend on
high uptake. An important element of this successful rollout is
a public that views the adopted prioritization system as fair and
equitable. If this is not the case, for whatever reasons, govern-
ments risk the types of public resistance and polarization that
occurred in some countries regarding the wearing of masks (22).
It also risks the creation of vaccine black markets that would
threaten the safety and fairness of vaccination campaigns. To
accomplish these goals, governments should seek evidence of
the public’s opinions and preferences regarding the groups to be
prioritized, public vs. private distribution channels, and manda-
tory requirements to be vaccinated. This information can aid in
the design of better policies and the implementation of success-
ful communication campaigns, both of which would help ensure
successful COVID-19 vaccination programs (23).
Study Design
To provide an evidence-based understanding of public opinions
on key aspects of vaccine allocation, we implemented online pub-
lic opinion surveys in 13 countries. In all countries, with the excep-
tion of India and Uganda, we employed quota sampling to ensure
that national samples matched the demographic profiles of each
country (India and Uganda are primarily samples of urban com-
munities). As the detailed discussion in SI Appendix indicates,
the distributions of key sample demographics resemble those of
their populations.† For many countries, the distribution of demo-
graphic factors in the sample matched the population. Median
incomes (individual and household) for the samples resemble
those for the population and typically deviate no more than 20%.
In most countries, the better educated were overrepresented, and
the lesser educated were underrepresented. Additionally, in some
countries (Chile, China, Colombia, and Uganda), young respon-
dents were overrepresented in the samples. In order to address
sample imbalances on key demographics, we implemented post-
stratification weighting—in SI Appendix, we describe the raking
procedure employed for estimating the weights and also provide
a description of the distributions of key demographics for the pre-
and postweighted samples.
The survey included a conjoint experiment to identify prefer-
ences for different vaccine prioritization schemes. Conjoint sur-
vey experiments are frequently employed to identify the impor-
tance individuals attribute to different features or characteristics
of choices (24). Examples include environmental migrants (25),
asylum seekers (26), and migration destinations (27). Ref. 28
employed conjoint experiments that generated 40 million deci-
sions to determine the ethical principles the public thinks should
guide self-driving cars.‡ In the case of policy-oriented survey
experiments, evidence suggests that the weights given to attribute
characteristics in conjoint survey experiments map closely to the
actual policy choices made by the population (30).
In our conjoint experiment, each of the 15,536 subjects made
eight binary choices over hypothetical vaccine recipients (a total
of 124,288 pairwise comparisons) who randomly varied on five
attributes: occupation, age, transmission status (risk of contract-
ing and transmitting the virus), risk of death from COVID-19,
and income.§ As Table 1 and subsequent rollouts have shown,
these five attributes have played particularly important roles
in the vaccine allocation policies employed by our sample of
countries.¶
Global COVID-19 Vaccine Allocation Priorities
We estimated the importance of specific characteristics of vac-
cine allocation priorities using linear probability models (LPMs).
†SI Appendix, section 3 describes in detail how the sampling was conducted and the
characteristics of the quota sample for the 13 countries.
‡Other recent policy-related illustrations of conjoint experiments include ref. 29.
§SI Appendix, Fig. S1 provides an example of the attributes and values that characterized
the two potential vaccine recipients presented to respondents. Checking the propor-
tion of times individual conjoint levels were shown to subjects confirms that they were
adequately randomized (SI Appendix, Table S2).
¶It is important to point out that we did not have any strong priors as to what should
constitute the complete set of attributes to present to respondents. We relied on the
comprehensive survey of government policies summarized in Table 1 to define this set
of allocation priority attributes for the conjoint experiment.
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Age Transmission Vulnerability infrastructure social care childcare
Australia X X X X X
Brazil X X X X X
Canada X X X X X
Chile X X X
China X X X X X
Colombia X X X
France X X X X X
India X X X
Italy X X X
Spain X X
Uganda X X
United Kingdom X X X
United States X X X X
For each pairwise choice, we regressed the participant’s binary
decision on dichotomous variables representing the attribute val-
ues of the five vaccine allocation attribute variables. First, we
conducted this analysis at the global level, and then, we con-
ducted this analysis at the level of each country. SI Appendix,
Tables S3 and S4 present the regression results.
Fig. 1 reports the coefficients from the LPM regression esti-
mated on the data pooled across the 13 countries, along with
their 95% CIs (clustered by country). The individual coeffi-
cients reflect the average marginal component effect (AMCE) of
choosing a profile given the presence of each attribute level (rel-
ative to a reference category, included as a dot with coefficient
zero). Respondents are about 10% more likely to select a vac-
cine recipient profile of someone over 65 y of age compared with
a profile of someone younger than 26. A potential vaccine recip-
ient employed in a key worker occupation is roughly 20% more
likely to be selected by global respondents compared with those
not working or nonkey workers who can work at home. Poten-
tial recipients with high risk of either transmission or death are
roughly 15% more likely to be selected than those with low risk
of either transmission or death.
Fig. 2 reports separate LPM models# for each country orga-
nized by four regions, with 95% CIs clustered by respondent.‖
There is no evidence in any of the 13 countries of respondents
treating all potential vaccine recipient profiles equally. With
respect to each of the five priority attributes, there is evidence
that the global public favors some profile attributes over others.
Moreover, the pattern of coefficient values across our sample of
13 countries is quite similar. The global public exhibits a surpris-
ing consensus on which population attributes should have priority
in the COVID-19 vaccine implementation efforts.∗∗
# Identical models, using the same dichotomous outcome variable, were estimated using
logistic regression with clustered SEs. The R code for estimating these models is pro-
vided in the replication materials available on Harvard Dataverse (https://dataverse.
harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/PMV0TG). The results are vir-
tually identical to those presented in the text.
‖The models generating the coefficient estimates in Fig. 2 are weighted to reflect their
respective populations. Details on the weighting methodology are presented in SI
Appendix. Results without weights are virtually identical to those summarized in Fig. 2
and are presented in SI Appendix, Fig. S2.
**Our results are noteworthy for the similarity in the AMCEs we estimate for the
attribute levels in each of the 13 countries we sampled. We believe this reflects a
global consensus regarding the allocation priorities for COVID-19 vaccines. We also
find that our results exhibit some small variation across countries—in particular, the
prioritization of lower-income individuals that is observed in some countries but not
others. It is interesting to note that other large multination conjoint survey projects
also find considerable cross-national similarities, although again, these results demon-
Age matters. Respondents in virtually all countries favor vac-
cine candidate recipients with age profiles greater than the young
25-y-old reference category. Additionally, there is evidence in a
number of countries suggesting that the two oldest age categories
(the 65- and 75-y-old profiles) were favored over the younger
25- and 40-y-old profiles. The one exception is China, where
the older 65- and 75-y-old profile attributes were less preferred
than the younger 25- and 40-y-old profile attributes. This distinct
preference in China for younger vaccine recipients might be a
function of the composition of the China sample, which is heavily
skewed toward younger participants. However, the results may
also reflect some caution in China over giving newly developed
vaccines to the elderly.
For a majority of the 13 countries in our study, the income
attributes of the potential vaccine recipients affect allocation
preferences. The reference category here is the lowest quin-
tile of the income distribution. In most middle- and low-income
countries (Brazil, Chile, Colombia, India, and Uganda), respon-
dents exhibit lower preferences for potential vaccine recipients
in the average- and high-income categories. We see a simi-
lar, although somewhat less pronounced, pattern for the United
States, Canada, China, Australia, and European countries. It is
worth pointing out that redistributive vaccine allocation pref-
erences seem particularly salient in those countries with higher
levels of income inequality.
Vaccine allocation preferences related to occupation are vir-
tually identical across all the sampled countries. The reference
category here is “not working.” In all of the countries, respon-
dents accorded similar vaccine priority to the not working profile
attribute and the “nonkey worker able to work at home” attribute.
The nonkey workers unable to work at home attribute had a sig-
nificantly positive impact on profile selection (relative to the not
working reference category). All of the “key worker” occupa-
tional attributes had a positive effect on vaccine recipient selec-
tion in all sampled countries. This key worker result is very much
consistent with the vaccine allocation priority plans employed
by the governments of our sampled countries (Table 1).
strate the ability of the design to detect distinct patterns on some key attributes that
vary cross-nationally; Bechtel and Scheve (31) report that on many climate change pol-
icy attributes, countries agree, although on sanction valuations, they disagree; Bansak
and coworkers (26) find that the European public agrees on many concerns regarding
asylum seekers but again, that the country samples disagree on others, such as rea-
sons for migrating and country of origin; the AMCEs estimated by ref. 32 are, for the
most part, similar for Spain and Italy, although they differ on support for corporate
tax increases; and ref. 27 finds distinct patterns of emigration destination preferences
for Chinese and Indian emigrants vs. their British and Chilean counterparts.
Duch et al.
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Highest 20% income level
Average income level
Lowest 20% income level
Key worker: Health and social care
Key worker: Police and fire−fighting
Key worker: Water and electricity service
Key worker: Factory worker
Key worker: Education and childcare
Non−Key worker: Cannot work at home
Non−Key worker: Can work at home
Not working
High risk (of transmission)
Moderate risk (of transmission)
Average risk (of transmission)
High (risk of death)
Moderate (risk of death)
Average (risk of death)
AMCE
Fig. 1. Vaccine candidate decisions pooled across the 13 countries. AMCEs
are reported for each attribute value. The 95% CIs are shown for each point
estimate, clustered by country.
As our review summarized in Table 1 indicated, many of the
governments of our sampled countries have prioritized COVID-
19 vaccination for individuals who are at high risk of death from
the virus and to a lesser extent, those at high risk of contracting
and transmitting the virus. Similarly, in Fig. 2, we see that vaccine
allocation profiles with “high risk of COVID-19 death” and high
risk of “COVID-19 contracting and transmitting” were signifi-
cantly more likely to be selected by respondents in all 13 country
samples.
Segments of the population may display quite different views
on vaccine allocation priorities. Fig. 3 explores this possible het-
erogeneity by breaking down the main conjoint analysis by age,
income, and left–right political self-identification (since we pool
observations across countries and estimate conditional effects,
these models do not weight observations). Overall, the effects
of the attributes were broadly similar across the different sub-
groups. As to which vaccine recipient attributes should be pri-
oritized, there is a general consensus among those identifying
with the left and the right, young and old, less and more highly
educated, and richer and poorer citizens. SI Appendix, Fig. S3
presents results from additional subgroup analyses that indicate
that women and men; those who are high and low educated; and
those with high, moderate, and low concerns about COVID-19
vaccine side effects all agree on the vaccine recipient attributes
that should be prioritized. This is a diverse set of possible sources
of heterogeneous treatment effects. This absence of heterogene-
ity here suggests that preferences regarding vaccine priorities are
not affected by self-interest, political partisanship, concern about
vaccine side effects, or educational attainment. Instead, they
reflect broad societal consensuses on who should be vaccinated.
Global COVID-19 Allocation Mechanisms
Implementing COVID-19 vaccination programs is challenging.
The COVID-19 vaccines are a public good, and the general pub-
lic has expectations regarding how this public good should be
provided, specifically what vaccine allocation mechanisms are
appropriate or acceptable. The global survey included ques-
tions measuring preferences for how governments should imple-
ment the vaccination program. The results, summarized in Fig.
4, suggest that the public is not indifferent to the allocation
mechanisms put in place.††
First, there is evidence of a global consensus on the important
role of government distribution. Respondents in the survey were
asked whether COVID-19 vaccines should be made available
through government distribution alone, government distribution
and private sale, or only private sale. Fig. 4A confirms that a
very large majority of the public believes the government should
assume the lead role in the distribution of COVID-19 vaccines.
Moreover, this result is consistent across each of the 13 countries;
at least two-thirds of the population in each country said that
distribution should only be available via government schemes.
Nevertheless, in most countries there are still substantial per-
centages of the population who feel there should be at least some
role for private distribution; this ranges from 13% in Canada to
28% in Chile.
While a majority in all countries think COVID-19 vaccine
distribution should be solely via government schemes, there is
evidence that a large proportion would be willing to pay for a
vaccine if it was available privately. We asked respondents, “If a
COVID-19 vaccine was also available for private purchase and
you could receive it immediately [rather than wait 6 mo], would
you considering buying it?” Fig. 4B suggests that roughly half
of our global sample would be willing to purchase a COVID-
19 vaccine on the private market, ranging from 18% in France
to 79% in India and Uganda. The low- and middle-income coun-
tries were particularly enthusiastic about purchasing the vaccine
on the private market (while at the same time, strongly favoring
government provision).
Fig. 4 indicates that there are countries in which public sup-
port for some private provision of COVID-19 vaccines is rela-
tively high—exceeding 20% of the sampled respondents. It does
appear that support for private provision is particularly high in
countries that are typically characterized as having weak state
capacity and hence, where citizens might be skeptical about the
government’s ability to efficiently allocate COVID-19 vaccines.
We explored this conjecture by measuring state capacity for 13
countries with the 2019 government efficiency metric from the
Worldwide Governance Indicators (WGI) (33). As we would
expect, there is a negative correlation between the WGI indica-
tor (that varies between a low score of −2.5 and a high score of
2.5) and the percentage of the sample favoring either private or a
mix of government and private provision of the vaccine. The cor-
relation is −0.30 for the whole sample of 13 countries. Uganda is
an outlier in that it has a surprisingly low preference for private
provision. Excluding Uganda, the correlation is −0.62. These
††The exact wording of these questions is reported in Materials and Methods.
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Highest 20% income level
Average income level
Lowest 20% income level
Key worker: Health and social care
Key worker: Police and fire−fighting
Key worker: Water and electricity service
Key worker: Factory worker
Key worker: Education and childcare
Non−Key worker: Cannot work at home
Non−Key worker: Can work at home
Not working
High risk (of transmission)
Moderate risk (of transmission)
Average risk (of transmission)
High (risk of death)
Moderate (risk of death)
















































Fig. 2. Vaccine candidate decisions by country. AMCEs are reported for each attribute value. The 95% CIs are shown for each point estimate, clustered by
subject. Models are weighted to reflect the respective national populations, excluding India and Uganda, which represent primarily urban samples.
correlations are suggestive; the public in weak-capacity states
seem to be more enthusiastic about private provision than is the
case in the higher-capacity states in our sample.
There is no consensus as to whether the COVID-19 vac-
cine should be mandatory, either across the national samples or
within countries. We asked respondents to indicate on a scale
from 0 (very much disagree) to 100 (very much agree) how much
they agreed or disagreed with the statement “the government
should make the COVID-19 vaccine mandatory for everybody.”
As Fig. 4C indicates, opinion overall is skewed toward making
COVID-19 vaccination mandatory. However, there is evidence
of some polarization. In a number of countries, there is substan-
tial clustering of responses at both ends of the scale. About 24%
of our global sample were strongly opposed to mandatory vacci-
nation, while about 38% were strongly in favor. There was vari-
ation among countries. In France, there was a broad consensus
of opinion strongly opposing mandatory vaccination (about 60%
opposed mandatory vaccination). Opinion was highly polarized
in the United States and the United Kingdom, with the majority
of people either strongly opposed to mandatory vaccination or
strongly supportive. Opinion was also somewhat polarized, with
little middle ground, in Australia, Brazil, Chile, and Colombia—
but with a much larger cluster supporting mandatory COVID-19
vaccination. In China, India, and Uganda, very few people were
strongly opposed to mandatory vaccination, and the majority
were strongly supportive. France stands out in that most of the
sample was opposed or indifferent to mandatory vaccination.
Discussion
This study undertook an online survey, based on quota sam-
pling, of 15,536 members of the general public in a diverse range
of countries to understand preferences and opinions regarding
the allocation of COVID-19 vaccines. To elicit preferences, we
undertook a large-scale conjoint experiment in which respon-
dents were asked to evaluate profiles of candidate recipients for
a COVID-19 vaccine. The profiles varied on a set of randomly
assigned attributes that corresponded to the major vaccine allo-
cation priorities being considered by policy makers. We found
that the public would prioritize people for vaccination based on
a broad range of factors. Not surprisingly, these include features
directly related to contracting COVID-19 or developing severe
symptoms, such as age, vulnerability, and risk of transmission.
Notably, however, the public would also prioritize according to
what might be deemed more economic factors, including low-
income groups and quite a wide range of nonhealth-related
key occupations (e.g., teachers) and nonkey workers who can-
not work from home. While there is substantial variation in
COVID-19 vaccine allocation policies in our sample of countries
Duch et al.
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Highest 20% income level
Average income level
Lowest 20% income level
Key worker: Health and social care
Key worker: Police and fire−fighting
Key worker: Water and electricity service
Key worker: Factory worker
Key worker: Education and childcare
Non−Key worker: Cannot work at home
Non−Key worker: Can work at home
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High risk (of transmission)
Moderate risk (of transmission)
Average risk (of transmission)
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Moderate (risk of death)







































Fig. 3. Vaccine candidate decisions by age, income, and left–right self-identification. AMCE estimates are reported for attribute values (observations are
pooled across countries). The 95% CIs are shown for each point estimate, clustered by country. Observation weights are not used.
(Table 1), public preferences for prioritization appear to be
largely consistent across countries and larger regions. Moreover,
when we estimated the conjoint model for subgroups in the sam-
ples, we found that preferences were consistent across a range of
respondent characteristics, such as age and income (Fig. 3).
It is important to note that in each country, our sample consists
of individuals with internet access via a computer or personal
device. As we have shown, the country samples, with some excep-
tions that we address by weighting, reflect their populations at
least on the observable measures we can benchmark against—
such as gender, education, income, and region (this is docu-
mented in SI Appendix). Nonetheless, an important limitation
here is that the online samples may differ from their populations
on important unobservable variables, such as political engage-
ment and general knowledge. This could bias our results. For
example, internet samples, in all countries, may attract dispro-
portionately policy-engaged individuals, which could contribute
to the homogeneity of treatment effects we observe across the
13 countries. Although if this was the case, we would expect out-
comes on other COVID-19 policy–related variables to also be
similar across our national samples. This is generally not the
case; the cross-national vaccine distribution preferences in Fig.
4 vary significantly across countries, as do their correlations with
ideology as shown in SI Appendix, Figs. S5–S7.
It is interesting to note that respondents from the right and
left responded remarkably similarly to this particular set of allo-
cation priorities. This suggests that there is certainly a range of
allocation policy priorities that would not be politically polariz-
ing. This, of course, does not exclude political polarization on
other aspects of the COVID-19 crisis. There is evidence, par-
ticularly from the US context, that attitudes and behaviors are
correlated with partisanship (34). We observe evidence of these
ideological cleavages in global preferences regarding how vac-
cines get distributed to the population, which are presented in
Fig. 4. In SI Appendix, section 2, we compare left/center vs. right
preferences for government-mandated vaccines, for government
vs. private distribution, and regarding the purchase of COVID-
19 vaccines privately. As we might expect, those self-identifying
on the right, in most countries, are significantly more willing
to purchase COVID-19 vaccines from a private supplier. The
exception is in Brazil, where the left seems more enthusiastic
about private purchases—although given the political situation
in Brazil at the time, this could be perfectly consistent with
the polarization narrative. Additionally, in a majority of the
countries, those identifying on the left are more likely to pre-
fer government provision of COVID-19 vaccines as opposed to
some mix of private and government allocation. In the United
States, for example, 77% of left/center respondents prefer a
government-only option compared with 61% of right-identifying
respondents. Only in India do we see this pattern significantly
reversed. Government-mandated vaccines receive higher sup-
port from right partisans than those from the left—in a majority
of countries, average support for mandates is higher among
right-identifying respondents.
Conjoint methods have been widely used to understand pref-
erences for other types of health care, including influenza
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Fig. 4. Allocation mechanism. Results are weighted to match national
population distributions. (A) Preference for government vs. private COVID-
19 vaccine distribution. (B) Willingness to purchase the COVID-19 vaccine
privately. (C) Agree that the government should mandate the COVID-19
vaccine.
vaccination, and have been shown to mimic real-world decision
making. However, it is important to note that our conjoint exper-
iment is largely intended to capture preferences for prioritizing
the access of others. Our analyses of heterogeneity indicate that
in many instances, respondents are willing to prioritize individu-
als who do not share their own characteristics. For example, those
aged over 65 were found to have strong preferences for prioritiz-
ing many types of essential workers. It is difficult to disentangle
the degree to which these preferences are due to altruism; to a
desire to reduce the likelihood of being infected through interac-
tion with unvaccinated individuals; or more broadly, to a desire to
choose an optimal vaccination program that would help end the
pandemic and bring life back to normal sooner.‡‡
‡‡In related work that analyzes this 13-country survey, we also find what appears to be
altruistic attitudes regarding vaccine allocations. It is interesting to note that we find
that a majority of respondents from the developed economies in our sample expressed
support for donating at least 10% of their vaccine supplies to countries in need (35).
A limited number of studies have examined COVID-19 vac-
cine preferences at a national level. For example, a recent
survey of the Belgian population (15) found a preference for
vaccination of essential workers, those more likely to trans-
mit the virus, and those at high risk. Unlike our study, it did
not find any preference for allocation to those aged over 60.
An advantage of conducting comparative international studies
of preferences and opinions is the ability to provide evidence
on the degree to which public views are consistent across geo-
graphically, economically, and culturally diverse countries. While
there have been efforts to understand preferences for differ-
ent methods of social distancing (36) and the likely uptake of
COVID-19 vaccines (37), we have not found other comparable
international surveys that can help inform COVID-19 vaccine
allocation.
Our study also has important implications for vaccine prior-
itization policies. Importantly, in the countries in our sample,
there appears to be much greater heterogeneity in national poli-
cies (Table 1) than in public preferences. While policies have
typically included some of the groups that the public thinks
should be given priority (e.g., those at high risk of mortality),
there are only a minority of countries that have given priority
to vaccinating groups of key workers (such as teachers). Fur-
ther, our study indicates that the public feels that a broader set
of economic factors should be taken into account in prioritiza-
tion policies—these include low-income groups and nonessential
workers who cannot work from home. With regard to the former,
while some countries have stressed the importance of ensuring
good vaccine uptake among deprived groups, we are unaware
of any countries that are explicitly targeting people accord-
ing to levels of income or other markers of deprivation (7).
Beyond helping prioritize access in the initial rollout of COVID-
19 vaccines, it is likely that additional doses (potentially on an
annual basis) will be required for the foreseeable future. Hence,
there is a need for all countries to consider such factors when
developing ongoing policies to prioritize COVID-19 vaccine
access.
Regarding the mode of allocation, there is a remarkably
consistent preference for government-only allocation across all
countries (Fig. 4). Nevertheless, the public will pay for a COVID-
19 vaccine if it does become privately available. We saw in Fig. 4
that in many countries, a significant proportion indicated a will-
ingness to purchase it on the private market in order to receive
the vaccine faster. The highest proportions of those willing to
purchase privately are in low- and middle-income countries, such
as Brazil, Chile, India, and Uganda. Given the emergence of
companies that are gearing to supply privately (16), understand-
ing implications for both coverage and affordability should be a
priority. If COVID-19 vaccines are to be allocated privately, it
will be essential to develop policies to ensure that private alloca-
tion does not jeopardize a country’s ability to acquire the doses
necessary for government-managed vaccination campaigns. Ide-
ally, any private access would complement public provision to
maximize the health and economic gains of vaccination and
minimize the potential for corruption (38).
Successful vaccination policies for other diseases have some-
times involved incentive payments, penalties (39), or restrictions
(such as refusing attendance to schools without vaccination) (20).
Our survey shows that mandating COVID-19 vaccination com-
mands considerable support in our global sample. Mandated
COVID-19 vaccination, however, does polarize public opinion
in a number of countries, including in the United States and the
United Kingdom. In one sampled country, France, the public is
overwhelmingly opposed to mandated COVID-19 vaccination.
The development and communication of policies that in any way
mandate COVID-19 vaccination should carefully consider the
possible risk of creating a politically polarizing issue, as occurred
with the wearing of masks in the United States.
Duch et al.
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Our survey finds that a very diverse set of allocation priorities
is expressed by the general public. These encompass a concern
for protecting the most vulnerable and reducing transmission
while allowing life to return to normal and allowing productive
sectors of the economy to open. These preferences could be used
to help weight the multiple criteria on which to assess various
vaccination strategies.
These results should help inform the ongoing debate over
how COVID-19 vaccination programs should be implemented.
In particular, they identify opportunities for policy makers, who
have often struggled during the COVID-19 pandemic to meet
their obligations to protect public health and the economy while
simultaneously respecting the public will. While approaches to
lockdowns have been divisive and politicized, a positive message
from this study is that, with the exception of mandatory vacci-
nation, the public has generally consistent preferences regard-
ing vaccination programs, and these hold across political and
geographic divides.
This does not mean that government vaccination programs
should fully accord with public preferences. Designing optimal
vaccination programs is complex; there are many externalities
to consider, and there is a clear role for expert input (40). Yet,
these programmatic choices incorporate important implicit value
judgements, and the diversity of actual policies across countries
emphasizes the scope for experts to reach different conclusions.
At a minimum, governments should take stock of public opinion.
Governments, acting in the public interest, may enact vaccination
programs that prioritize groups differently than would the gen-
eral public. It is important, however, that governments recognize
these differences between policy choices and public preferences
and that these differences inform their efforts to gain public
acceptance of their COVID-19 vaccination programs.
Materials and Methods
Sample. The Oxford CANDOUR Project conducted online surveys of adults
over 18 y of age from 13 countries. The sample of countries included Aus-
tralia, Brazil, Canada, Chile, China, Colombia, France, India, Italy, Spain,
Uganda, the United States, and the United Kingdom. They account for
about half the global population and represent very diverse social and eco-
nomic contexts. In each country, we interviewed between 1,000 and 1,500
respondents during the period 24 November 2020 to 14 January 2021.
In all but Chile and Uganda, respondents were sampled by the sampling
firm, Respondi.§§ The Respondi participants were compensated for complet-
ing the survey. For these 12 countries, the modal incentive was $3.50 for a
median length of interview of 25.53 min. In Chile and Uganda, the respon-
dents were sampled using Facebook Ad Manager (41).¶¶ Respondents in
Chile received payments of $3.00, and in Uganda, they received $2.25.
We implemented a quota strategy that generated samples that roughly
matched the populations on age, education, gender, and region. Poststrat-
ification weights were constructed to account for remaining imbalances,
as explained below. Among the panelists invited to take our survey, the
response rate (calculated as the fraction of complete responses over invited,
eligible participants) was 21.3%, averaged across all countries. The final
sample included an average of 1,195 respondents per country (15,536
respondents overall). SI Appendix provides a detailed account of sampling
and weighting procedures along with descriptive statistics for the resulting
sample.
The survey was conducted according to the University of Oxford’s pol-
icy for human subjects research and approved by the University of Oxford
Medical Sciences Interdivisional Research Ethics Committee (approval ID:
R72328/RE001). Informed consent was obtained from each participant at the
beginning of the survey.
Experimental Design. A conjoint experiment was embedded at the begin-
ning of the CANDOUR questionnaire on the theme of the COVID-19 vaccine.
§§Further information on Respondi is available at https://www.respondi.com/EN/.
¶¶The recruitment advertisement is available with the replication materials avail-
able on Harvard Dataverse (https://dataverse.harvard.edu/dataset.xhtml?persistentId=
doi:10.7910/DVN/PMV0TG).
The experiment aimed to identify public preferences for which groups
should be prioritized to receive limited available doses of COVID-19 vac-
cine. As an introduction to the overall survey, respondents were presented
with a short definition of vaccines and how they work. Conjoint survey
experiments are frequently employed to identify the importance that indi-
viduals attribute to different features or characteristics of choices (24).
Examples include environmental migrants (25), asylum seekers (26), and
migration destinations (27). Awad et al. (28) employed conjoint experiments
that generate 40 million decisions to determine the ethical principles the
public thinks should guide machine behavior.## We implemented a stan-
dard fully randomized paired profiles conjoint design (SI Appendix, Fig.
S1 shows an example) in which each respondent was shown profiles of
two different hypothetical vaccine recipients displayed side by side (42).
In the case of policy-oriented survey experiments, evidence suggests that
the weights given to attribute characteristics in conjoint survey experiments
map closely to the actual policy choices the population would make in
real-world decisions, such as referendums (30).
In our conjoint experiment, each of the 15,536 subjects made eight binary
choices over hypothetical vaccine recipients (a total of 124,288 pairwise com-
parisons) who randomly varied on five attributes that are being used or have
been proposed as being important criteria for vaccine allocation.
Outcomes. As SI Appendix, Fig. S1 indicates, respondents were shown two
potential vaccine recipients (Person A and Person B). Respondents were first
asked to choose which of the potential recipients should receive the COVID-
19 vaccine immediately. The resulting choice outcome variable has a value of
one for the preferred profile and zero for the profile that was not selected.
SI Appendix, Table S2 presents the attributes and summarizes the distribu-
tion of the randomly assigned attribute values for the global sample (the
wording matches the English versions of the survey that were administered
in Australia, Canada, India, Uganda, the United Kingdom, and the United
States).
Survey Text. The conjoint experiment is the first section of the survey. The
experiment had a prelude introducing the vaccine allocation policy issue.
Respondents were then informed of the profile attributes. Following this,
respondents were asked a series of questions in which they were presented
with a pair of profiles. In each question, they were asked to choose between
the two profiles and then, to evaluate the extent to which their selected
profile should be prioritized on a seven-point Likert scale. The wording of
the items is as follows.
Prelude. Across the world, COVID-19 has infected tens of millions; killed
more than 1 million; and resulted in loss of jobs, school closures, and over-
all economic loss. A vaccination would prevent people from being affected
by the virus. It is like the flu vaccine. Some people who get the vaccine
could still get COVID-19 because it is not 100% effective, the protection
could last a few months or for years, and it could have side effects. Once
a reliable COVID-19 vaccine is available, health officials will give some indi-
viduals priority over others. Some individuals will get the COVID-19 vaccine
immediately, and other individuals will have lower priority. We are inter-
ested in your opinion about these decisions. In the next screens, you will
be shown two individuals (Person A and Person B) who have different char-
acteristics that are related to COVID-19. When each screen comes up, you
will be asked to choose the person (Person A or Person B) who should get
the COVID-19 vaccine immediately. You will be provided with five charac-
teristics for each individual, Person A and Person B. These five characteristics
are the following: if infected, the person’s risk of COVID-19–related death
compared with an average person; the person’s risk of catching and trans-
mitting the COVID-19 virus; the income level of the person; the occupation
status of the individual; and the age category of the person. We would like
you to indicate which of the two persons (Person A or Person B) should have
priority and receive the vaccine immediately.
Questions.
1) (Choice) As you can see, each of the persons (Person A and Person B)
differs on our five characteristics: risk of COVID-19–related death, risk of
catching and transmitting the COVID-19 virus, income level, occupation
status, and age category. This vaccine could be given to one of these per-
sons (Person A or Person B) immediately. Please indicate the person you
think should get the vaccine immediately. Which of the persons do you
think should get the vaccine immediately? Select one of them: Person A
or Person B.
##Other recent policy-related illustrations of conjoint experiments include ref. 29.
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2) (Rating) Person A. On a scale from one to seven, where one indicates
that you think Person A should get very low priority for the vaccine and
seven indicates that you think Person A should get very high priority for
the vaccine, what vaccine priority would you give Person A?
The survey instrument included a number of different themes in addition
to the conjoint experiment. A full version of the survey instrument is
available with the replication materials available on Harvard Dataverse
(https://dataverse.harvard.edu/dataset.xhtml?persistentId=doi:10.7910/DVN/
PMV0TGhttps://doi.org/10.7910/DVN/PMV0TG). Here, we present the
wording of the questions presented in Fig. 4.
• Talking about vaccines in general, in some countries vaccines are only
available from the government either at low or no cost. In some coun-
tries, vaccines are only available for private purchase. Additionally, in
some countries, vaccines are available from the government, but citizens
can pay privately to gain early access. Which of these three approaches do
you think should be applied to the COVID-19 vaccine? Would you prefer
–vaccines only made available by the government at low or no cost?
–vaccines only available for private purchase?
–vaccines made available by the government but citizens can pay privately
to gain access?
• Consider the following situation. A COVID-19 vaccine becomes available
and is provided by government health agencies. For 80 of 100 people, the
vaccine would provide protection for at least 18 mo. However, there are
limited initial supplies of the vaccine. For this reason, you would have to
wait 6 mo before you could receive it. If a COVID-19 vaccine was also avail-





• We are interested in your opinion about the implementation of the
COVID-19 vaccine after it is available. Please use the sliding scale to indi-
cate how much you agree or disagree with the statements. You can move
the pointer from 0, which means very much disagree, to 100, which means
very much agree.
–The government should make the COVID-19 vaccine mandatory for
everybody.
Survey Translations. The survey was translated from English into five lan-
guages: Chinese, French, Italian, Spanish, and Portuguese. These translations
were conducted by professional translators. They were reviewed by a
number of native speakers. They were then translated back to English.
Statistical Analysis. The 15,536 respondents from the 13-country sample
viewed eight pairs of vaccine allocation profiles and made a forced choice
(i.e., there was no opt-out option). This generated 248,576 profile eval-
uations. Our goal in the multivariable modeling of these dichotomous
outcomes was simply to identify which of the attribute values were more
(or less) likely to cause respondents to select a particular profile. We report
in the text the AMCEs of each attribute on respondents’ choice of a vac-
cine allocation priority, which we were able to identify due to the total
random assignment of attribute values across all profiles and respondents
(42). To estimate these AMCEs, we employed linear least squares regres-
sion. We regressed the forced vaccine allocation priority choice on sets
of indicator variables that represent the values of each attribute while
omitting one level of each attribute as the reference category. SEs are
clustered by respondent in the individual country models and by coun-
try in the pooled, heterogeneous effects models. We also estimated the
same forced choice model employing logistic regression—these regressions
generated substantively identical results to those from the ordinary least
squares regressions reported in the manuscript. The R code for estimating
the logistic regression models is supplied in the replication materials avail-
able on Harvard Dataverse (https://dataverse.harvard.edu/dataset.xhtml?
persistentId=doi:10.7910/DVN/PMV0TG).
Data Availability. All data, code, and other materials required to repro-
duce the results fully are publicly available at Harvard Dataverse, https://
dataverse.harvard.edu/citation?persistentId=doi:10.7910/DVN/PMV0TG (43).
Previously published data were used as part of this work (33).
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25. G. Spilker, V. Koubi, T. Böhmelt, Attitudes of urban residents towards environmental
migration in Kenya and Vietnam. Nat. Clim. Chang. 10, 622–627 (2020).
26. K. Bansak, J. Hainmueller, D. Hangartner, How economic, humanitarian, and religious
concerns shape European attitudes toward asylum seekers. Science 354, 217–222
(2016).
27. R.M. Duch, D. Laroze, C. Reinprecht, T.S. Robinson, Nativist policy: The comparative
effects of Trumpian politics on migration decisions. Polit. Sci. Res. Methods 100, 1–17
(2020).
28. E. Awad et al., The moral machine experiment. Nature 563, 59–64 (2018).
29. L. F. Beiser-McGrath, T. Bernauer, Could revenue recycling make effective carbon
taxation politically feasible? Sci. Adv. 5, eaax3323 (2019).
30. J. Hainmueller, D. Hangartner, T. Yamamoto, Validating vignette and conjoint survey
experiments against real-world behavior. Proc. Natl. Acad. Sci. U.S.A. 112, 2395–2400
(2015).
31. M. M. Bechtel, K. F. Scheve, Mass support for global climate agreements depends on
institutional design. Proc. Natl. Acad. Sci. U.S.A. 110, 13763–13768 (2013).
32. K. Bansak, M. M. Bechtel, M. Yotam, Why austerity? The mass politics of a contested
policy. Am. Polit. Sci. Rev. 115, 486–505 (2021).
33. D. Kaufmann, A. Kraay, Worldwide governance indicators. World Bank (2021).
https://info.worldbank.org/governance/wgi/Home/Documents#doc-intro. Accessed
8 June 2021.
34. A. Gollwitzer et al., Partisan differences in physical distancing are linked to health
outcomes during the COVID-19 pandemic. Nat. Hum. Behav. 4, 1186–1197 (2020).
35. P. M. Clarke et al., Public opinion on global rollout of COVID-19 vaccines. Nat. Med.
27, 935–936 (2021).
36. N. W. Papageorge et al., Socio-demographic factors associated with self-protecting
behavior during the Covid-19 pandemic. J. Popul. Econ. 34, 691–738 (2021).
37. J. V. Lazarus et al., A global survey of potential acceptance of a COVID-19 vaccine.
Nat. Med. 27, 225–228 (2021).
38. J. C. Kohler, T. Wright, The urgent need for transparent and accountable procurement
of medicine and medical supplies in times of COVID-19 pandemic. J. Pharm. Policy
Pract. 13, 58 (2020).
39. B. P. Hull, F. H. Beard, A. J. Hendry, A. Dey, K. Macartney, “No jab, no pay”: Catch-up
vaccination activity during its first two years. Med. J. Aust. 213, 364–369 (2020).
40. L. S. J. Roope et al., How should a safe and effective COVID-19 vaccine be allocated?
Health economists need to be ready to take the baton. Pharmacoeconom. Open 4,
557–561 (2020).
41. B. Zhang et al., Quota sampling using Facebook advertisements. Political Sci. Res.
Methods 8, 558–564 (2020).
42. J. Hainmueller, D. J. Hopkins, T. Yamamoto, Causal inference in conjoint analysis:
Understanding multidimensional choices via stated preference experiments. Polit.
Anal. 22, 1–30 (2014).
43. R. Duch et al., Replication data for: “Citizens from 13 countries share similar
preferences for COVID-19 vaccine allocation priorities.” Harvard Dataverse. https://
dataverse.harvard.edu/citation?persistentId=doi:10.7910/DVN/PMV0TG. Deposited
25 August 2021.
10 of 10 | PNAS
https://doi.org/10.1073/pnas.2026382118
Duch et al.
Citizens from 13 countries share similar preferences for COVID-19 vaccine allocation priorities
D
ow
nl
oa
de
d 
by
 g
ue
st
 o
n 
S
ep
te
m
be
r 
16
, 2
02
1 
